Market Overview

Immunomedics Announces Preclinical Study Showed Epratuzumab's B-Cell Modulation Effect Elucidated

Related IMMU
Earnings Scheduled For August 25, 2014
Immunomedics' IMMU-132 Gets Orphan Drug Status - Analyst Blog

Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported that its lead antibody drug candidate, epratuzumab, has a distinct way of reducing the immune response of B cells, which, in an autoimmune disease such as lupus, are responsible for producing antibodies that attack the patient's own body.

Posted-In: News FDA

 

Related Articles (IMMU)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters